Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer
The DOI matches its Crossref record.
Abstract
Background: The Phase III IMpassion130 study (NCT02425891) evaluated atezolizumab (anti–PD-L1) + nab-paclitaxel (nabPx) vs placebo + nabPx as first-line treatment for pts with metastatic triple-negative breast cancer (TNBC). The study met its co-primary PFS endpoint in ITT pts and in pts with PD-L1 ≥1% on tumor-infiltrating immune cells (IC+). Clinically meaningful OS benefit was seen at interim OS analysis, notably in pts with PD-L1 IC+ tumors (Table). Here we report exploratory efficacy data in immunologically and clinically relevant, biomarker-defined subgroups. Methods: Pts had histologically documented metastatic or unresectable locally advanced TNBC (evaluated locally per ASCO-CAP). Pts were randomized 1:1 to nabPx 100 mg/m2 IV (d1, 8 and 15 of a 28-d cycle) + atezolizumab 840 mg IV q2w or placebo (A-nabPx or P-nabPx) until progression or toxicity. Exploratory biomarkers were centrally analyzed: PD-L1 on tumor cells (TC) by VENTANA SP142 IHC assay, intratumoral CD8 by IHC, stromal tumor-infiltrating lymphocytes (sTILs), BRCA1/2 mutational status and ER/PR/HER2 status. Results: PD-L1 IC was highly predictive of A-nabPx efficacy (Table). The majority of PD-L1 TC+ tumors were also PD-L1 IC+. Intratumoral CD8, but not sTILs, were well correlated with PD-L1 IC. Consequently, CD8 was predictive of A-nabPx efficacy for PFS/OS, while sTILs only predicted PFS benefit. Local vs central TNBC assessment was concordant in most pts. Local vs central lab–defined TNBC populations derived similar benefit from A-nabPx. Efficacy by BRCA status will be presented to evaluate the benefits of immunotherapy for this subgroup. Conclusions: Exploratory efficacy analyses from IMpassion130 suggest consistency between local and central ER/PR/HER2 testing and that PD-L1 IC is the most robust predictive biomarker for selecting untreated mTNBC pts who benefit from A-nabPx. PopulationA-nabPxP-nabPxPrimary data, stratifiedITT, n451451mPFS (95% CI), mo7.2 (5.6-7.5)5.5 (5.3-5.6)PFS HR (95% CI)0.80 (0.69-0.92); P=0.0025mOS (95% CI), mo21.3 (17.3-23.4)17.6 (15.9-20.0)OS HR (95% CI)0.84 (0.69-1.02); P=0.0840PD-L1 IC+, n (%)185 (41%)184 (41%)mPFS (95% CI), mo7.5 (6.7-9.2)5.0 (3.8-5.6)PFS HR (95% CI)0.62 (0.49-0.78); P<0.0001mOS (95% CI) mo25.0 (22.6-NE)15.5 (13.1-19.4)OS HR (95% CI)0.62 (0.45-0.86)aExploratory/biomarker data, unstratifiedPD-L1 TC evaluable, n449451PD-L1 TC+, n (%)38 (8%)40 (9%)PFS HR (95% CI)0.51 (0.31-0.84)OS HR (95% CI)0.63 (0.33-1.21)CD8 evaluable, n371349CD8 ≥0.5%, n (%)261 (70%)239 (68%)PFS HR (95% CI)0.74 (0.61-0.91)OS HR (95% CI)0.66 (0.50-0.88)sTIL evaluable, n448444sTIL ≥10%, n (%)147 (33%)137 (31%)PFS HR (95% CI)0.66 (0.50-0.86)OS HR (95% CI)0.75 (0.51-1.10)cTNBC evaluable, n420412cTNBC ITT, n (%)307 (73%)317 (77%)PFS HR (95% CI)0.81 (0.68-0.98)OS HR (95% CI)0.85 (0.67-1.08)cTNBC PD-L1 IC+, n (%)133 (43%)134 (42%)PFS HR (95% CI)0.67 (0.51-0.88)OS HR (95% CI)0.69 (0.47-1.00)Data cutoff: 17 April 2018 (12.9-mo median follow up).cTNBC, centrally confirmed TNBCTC/IC+, PD-L1 ≥1% (VENTANA SP142 assay)a Not formally tested per hierarchical study design. Citation Format: Emens LA, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Molinero L, Nguyen Duc A, Funke R, Chui SY, Husain A, Winer EP, Adams S, Schmid P. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS1-04.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Self-citationRole of Immunotherapy in Triple-Negative Breast Cancer
Keenan, T. E., & Tolaney, S. M. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7554 · Cited by 606
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Metadata
- Authors
- Emens, L., Loi, S., Rugo, H., Schneeweiss, A., Diéras, V, Iwata, H., Barrios, C., Nechaeva, M., Molinero, L., Nguyen Duc, A., Funke, R., Chui, S., Husain, A., Winer, E., Adams, S., & Schmid, P.
- Venue
- Cancer Research
- Published
- 2019-02-15
- Volume
- 79
- Issue
- 4_Supplement
- Pages
- GS1-04-GS1-04
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2944446380
- Cited by
- 81
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. https://app.cochat.ai/papers/10.1158/1538-7445.sabcs18-gs1-04
- The paper
- Emens, L., Loi, S., Rugo, H., Schneeweiss, A., Diéras, V, Iwata, H., Barrios, C., Nechaeva, M., Molinero, L., Nguyen Duc, A., Funke, R., Chui, S., Husain, A., Winer, E., Adams, S., & Schmid, P. (2019). Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Cancer Research. https://doi.org/10.1158/1538-7445.sabcs18-gs1-04
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.